--- title: "Tempest Therapeutics | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/281022174.md" datetime: "2026-03-30T12:43:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281022174.md) - [en](https://longbridge.com/en/news/281022174.md) - [zh-HK](https://longbridge.com/zh-HK/news/281022174.md) --- # Tempest Therapeutics | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -6.33, missing the estimate of USD -6.1. Tempest Therapeutics, Inc. operates as one reportable and operating segment, focusing on the discovery and development of small molecule drugs to treat cancers, with all assets and operations located in the U.S. The company has never generated any revenue from product sales and does not expect to generate product revenues for the foreseeable future due to the absence of regulatory approvals for its product candidates. Tempest Therapeutics, Inc. has incurred substantial operating losses . #### Net Loss For the year ended December 31, 2025, the net loss was - $26,262 thousand, a decrease of - $15,581 thousand or -37% compared to the net loss of - $41,843 thousand for the year ended December 31, 2024 . #### Operating Loss The operating loss for the year ended December 31, 2025, was - $26,575 thousand, a decrease of - $15,451 thousand or -37% from the - $42,026 thousand reported for the year ended December 31, 2024 . #### Research and Development (R&D) Expense Total R&D expense decreased by - $15,870 thousand (-56%) to $12,606 thousand for the year ended December 31, 2025, from $28,476 thousand in 2024, primarily due to re-prioritizing efforts towards exploring strategic alternatives . Amezalpat R&D costs decreased to $5,428 thousand in 2025 from $14,206 thousand in 2024 . TPST-1495 R&D costs decreased to $0 thousand in 2025 from $2,307 thousand in 2024 . Preclinical and other R&D costs decreased to $1,108 thousand in 2025 from $2,279 thousand in 2024 . Total candidate-specific research costs decreased to $6,536 thousand in 2025 from $18,792 thousand in 2024 . Personnel and other R&D costs decreased to $4,677 thousand in 2025 from $7,108 thousand in 2024 . Stock-based compensation and depreciation (R&D) decreased to $1,393 thousand in 2025 from $2,576 thousand in 2024 . #### General and Administrative (G&A) Expenses G&A expenses increased by $419 thousand (3%) to $13,969 thousand for the year ended December 31, 2025, from $13,550 thousand in 2024, primarily due to employee compensation costs, including one-time separation costs from a reduction-in-force in April 2025, as well as consulting and professional services . #### Other Income (Expense), Net Total interest expense was - $207 thousand in 2025, down from - $1,316 thousand in 2024, related to the Oxford Loan which was fully repaid and terminated in April 2025 . Interest income and other income (expense), net, was $520 thousand in 2025, compared to $1,499 thousand in 2024 . #### Cash and Cash Equivalents As of December 31, 2025, cash and cash equivalents totaled $7,707 thousand, a decrease from $30,268 thousand as of December 31, 2024 . #### Accumulated Deficit As of December 31, 2025, the accumulated deficit was - $233,368 thousand, an increase from - $207,106 thousand as of December 31, 2024 . #### Cash Flows - Cash used in operating activities was - $26,820 thousand for the year ended December 31, 2025, compared to - $33,027 thousand in 2024 . - Cash used in investing activities was $0 thousand for the year ended December 31, 2025, compared to - $435 thousand in 2024, primarily for property and equipment purchases . - Cash provided by financing activities was $4,259 thousand for the year ended December 31, 2025, compared to $24,500 thousand in 2024 . #### Outlook Tempest Therapeutics, Inc. expects its existing cash and cash equivalents to fund projected operating expense requirements for less than 12 months, raising substantial doubt about its ability to continue as a going concern . The company will rely on additional financing, including a funding commitment from Factor for up to $20.0 million, though there is uncertainty regarding satisfying its terms . Tempest Therapeutics, Inc. anticipates continued substantial operating losses for the foreseeable future until product development and approval are complete . ### Related Stocks - [TPST.US](https://longbridge.com/en/quote/TPST.US.md) ## Related News & Research - [Tempest Therapeutics Q1 net loss widens on asset acquisition costs](https://longbridge.com/en/news/286464103.md) - [Tempest Therapeutics Secures Up To $6 Million To Advance Clinical Pipeline, Stock Plunges](https://longbridge.com/en/news/280274061.md) - [Tempest Minerals Drops Zealandia Deal to Refocus on WA Projects](https://longbridge.com/en/news/287239711.md) - [Envoy Medical Flags Limited Risk Detail, Urges Investors to Review 2026 Form 10-K for Key Uncertainties](https://longbridge.com/en/news/286046067.md) - [DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing | DSS Stock News](https://longbridge.com/en/news/285775825.md)